Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT02773368

Public ClinicalTrials.gov record NCT02773368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i

Study identification

NCT ID
NCT02773368
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
420 participants

Conditions and interventions

Interventions

  • insulin degludec/liraglutide Drug
  • insulin glargine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 22, 2016
Primary completion
Sep 25, 2017
Completion
Oct 22, 2017
Last update posted
Aug 10, 2020

2016 – 2017

United States locations

U.S. sites
24
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Novo Nordisk Investigational Site Glendale Arizona 85308
Novo Nordisk Investigational Site La Jolla California 92037
Novo Nordisk Investigational Site Mission Viejo California 92691
Novo Nordisk Investigational Site Northridge California 91325
Novo Nordisk Investigational Site Palm Springs California 92262
Novo Nordisk Investigational Site San Ramon California 94583
Novo Nordisk Investigational Site Boynton Beach Florida 33472
Novo Nordisk Investigational Site Chiefland Florida 32626
Novo Nordisk Investigational Site Skokie Illinois 60077
Novo Nordisk Investigational Site Avon Indiana 46123
Novo Nordisk Investigational Site Rockville Maryland 20852
Novo Nordisk Investigational Site Las Vegas Nevada 89118
Novo Nordisk Investigational Site Teaneck New Jersey 07666
Novo Nordisk Investigational Site Albany New York 12206
Novo Nordisk Investigational Site West Seneca New York 14224
Novo Nordisk Investigational Site Whiteville North Carolina 28472
Novo Nordisk Investigational Site Mason Ohio 45040-6815
Novo Nordisk Investigational Site Greer South Carolina 29651
Novo Nordisk Investigational Site Bristol Tennessee 37620-7352
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Houston Texas 77081
Novo Nordisk Investigational Site Longview Texas 75605
Novo Nordisk Investigational Site San Antonio Texas 78228-3419
Novo Nordisk Investigational Site Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02773368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2020 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02773368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →